XOMA to Present at the Piper Jaffray Healthcare Conference
November 26 2013 - 1:00PM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, announced today John Varian,
the company's Chief Executive Officer, is scheduled to present at
the 25th Annual Piper Jaffray Healthcare Conference on December 4,
2013, at 2:00 p.m. EST, at The New York Palace Hotel.
A live audio webcast of the presentation can be accessed in the
Investors and Media section of XOMA's website at
http://investors.xoma.com/events.cfm. An archived version of the
webcast will be available via replay for 30 days following the
presentation.
About XOMA Corporation
XOMA's portfolio of innovative product candidates is the result
of the Company's focus on allosteric modulation, which offers
opportunities to develop new classes of therapeutic antibodies with
the potential to treat a wide range of human diseases. XOMA is
developing its lead product gevokizumab (IL-1 beta modulating
antibody) with SERVIER through a global Phase 3 program in
non-infectious uveitis and ongoing proof-of-concept studies in
other IL-1-mediated diseases. XOMA's scientific research also
produced the XMet program, which consists of three classes of
preclinical antibodies, including Selective Insulin Receptor
Modulators (SIRMs) that could have a major effect on the treatment
of diabetes.
More detailed information can be found at
www.xoma.com.
CONTACT: Company and Investor Contacts:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media Contact:
Canale Communications
Carolyn Hawley
619-849-5375
carolyn@canalecomm.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024